A Phase 3 interventional study of Torvutatug samrotecan and Bevacizumab in Epithelial Ovarian Cancer, sponsored by AstraZeneca. Recruiting at 220 sites in 29 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Carcinoma, Ovarian Epithelial with a site in China — 30 open to participants now, 37 under way, 12 of them phase 3. Carcinoma, Ovarian Epithelial · China.
Among the 71 studies in Carcinoma, Ovarian Epithelial with a site in China, this one is the 3rd largest by planned enrollment of the 53 interventional ones that give a count, is one of 10 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 34 of the 36 other live ones, and was the 70th registered.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
Browse Carcinoma, Ovarian Epithelial studies →30 of the 71 studies in Carcinoma, Ovarian Epithelial with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China, United States, Australia and 10 more countries
Ages 18+ · Women only
Beijing Biotech · Sites in China
Ages 18–75 · Women only
Beijing Biotech · Sites in China
Ages 18–75 · Women only
Beijing Biotech · Sites in China
Ages 18–75 · Women only
AstraZeneca · Sites in China, United States, Australia and 21 more countries
Ages 18+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 22 · Phase 3 22 · Phase 4 1
First in 2013; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 950 is above the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Median enrollment 94 across the 53 interventional studies, 270 across the 18 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 71 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 7 studies filed under Carcinoma, Ovarian Epithelial — fewer than ten, so there is no comparison to draw.
8 of the studies in Carcinoma, Ovarian Epithelial with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341907Phase 3Second Affiliated Hospital of Wenzhou Medical UniversityApplication of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | 2026-12-31 |
| NCT02859038Phase 3Shanghai Gynecologic Oncology GroupStudy of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer (SUNNY) | 2027-06 |
| NCT06994195Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | 2027-06 |
| NCT07480954Beijing BiotechDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) | 2027-02-17 |
| NCT07589543Beijing BiotechDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer | 2027-03-14 |
Add all 8 to your calendar (.ics) → With an account.
Among the 71 studies in Carcinoma, Ovarian Epithelial with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.
This study aims to see if maintenance treatment with torvu-sam in combination with bevacizumab allows patients to live longer without the cancer getting worse, compared to patients receiving bevacizumab.
Eligible patients will be those with advanced ovarian cancer who have not progressed following completion of first-line platinum-based chemotherapy (PBC) and bevacizumab.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Torvutatug samrotecan IV (intravenous) + Bevacizumab IV
Drug: Torvutatug samrotecan · Drug: Bevacizumab
Bevacizumab IV
Drug: Bevacizumab
Antibody drug conjugate
Also known as: AZD5335, Torvu-sam
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor
Also known as: Avastin, Vegzelma
Progression Free Survival (PFS)
PFS is defined as the time from randomization to radiographic progression as assessed by BICR per RECIST v1.1, or death due to any cause.
Time frame: up to approximately 5 years
Overall Survival (OS)
OS is defined as the time from randomization until the date of death due to any cause.
Time frame: up to approximately 7 years
Second progression free survival (PFS2)
PFS2 is defined as time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression) after first subsequent therapy, or death.
Time frame: up to approximately 5 years
Time to First Subsequent Therapy (TFST)
TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
Time frame: up to approximately 7 years
Time to Second Subsequent Therapy (TSST)
TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
Time frame: up to approximately 7 years
Health-related Quality of Life (HrQoL)
Change from baseline and time to deterioration in global health status/quality of life (GHS/QoL), physical functioning (PF), and ovarian cancer symptoms (EORTC IL433).
Time frame: up to approximately 5 years
Number and percentage of participants with adverse events as graded by CTCAE v6 criteria
Adverse Event Incidence
Time frame: up to approximately 7 years
Showing the first 100 of 220 sites across 29 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2030, 45 months after the start.
Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's planned 45 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Torvutatug samrotecan
Carcinoma, Ovarian Epithelial →